Denali Therapeutics outlines 2026 milestones including Hunter syndrome launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P, Nasdaq futures slip as markets await Iran sanctions, Nvidia results
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 6, 2026 8:00 AM ESTPreparing for FDA approval and commercial launch of tividenofusp alfa, Denalis TransportVehicle (TV)-enabled investigational therapy for Hunter syndromeExpecting multiple clinical data readouts from pipeline programs including for Sanfilippo syndrome Type A (ETV:SGSH), granulin-related frontotemporal dementia (PTV:PGRN) and Parkinsons disease (LRRK2 inhibitor)Planning for initiation of first-in-human clinical studies with TV-enabled therapeutics for Alzheimers disease (OTV:MAPT, ATV:Abeta) and Pompe disease (ETV:GAA)Continuing to strengthen leadership in... More
